ArticleArchives of microbiology2026
Experimental characterization of Pleurotus tuber-regium-derived silver nanoparticles and antifungal activity against Aspergillus fumigatus, Cryptococcus neoformans, and Candida albicans.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mushroom-mediated silver nanoparticles (AgNPs) offer a lower-reagent synthetic route to antifungal nanomaterials, but the contribution of Pleurotus tuber-regium sclerotial chemistry and activity across morphologically distinct opportunistic fungi remain insufficiently defined. In this experimental study, an aqueous sclerotial extract was characterized by gas chromatography-mass spectrometry (GC-MS) and used to synthesize P. tuber-regium-derived AgNPs (Pt-AgNPs). Data from three independent synthesis batches were evaluated by ultraviolet-visible spectroscopy, Fourier-transform infrared spectroscopy, X-ray diffraction (XRD), transmission electron microscopy (TEM), dynamic light scattering (DLS), zeta potential analysis, and energy-dispersive X-ray spectroscopy (EDX). The resulting Pt-AgNPs showed a surface-plasmon peak at 421.7 ± 2.1 nm, a TEM diameter of 24.8 ± 5.4 nm, a DLS Z-average of 68.7 ± 3.8 nm, a polydispersity index of 0.246 ± 0.021, and a zeta potential of -26.4 ± 1.9 mV. Broth microdilution was performed using Clinical and Laboratory Standards Institute M38 and M27 procedures. Modal minimum inhibitory concentrations were 8, 4, and 4 µg/mL for Aspergillus fumigatus, Cryptococcus neoformans, and Candida albicans, respectively. Across 4-128 µg/mL, Pt-AgNPs produced larger inhibition zones than crude extract for each species (formulation effects, all p < 0.001). At 2× MIC, viable counts fell by at least 3 log10 CFU/mL by 12 h for A. fumigatus and C. neoformans. These findings provide an integrated characterization and antifungal-testing dataset and warrant further experimental validation across a broader isolate panel, mechanistic investigation, and safety assessment.
Indexed as
Identifiers
42859228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.